Stock Track | Harrow Health Plummets 19.59% in Pre-Market on Earnings Miss and Below-Estimate 2026 Revenue Guidance

Stock Track
03/03

Harrow Health Inc. (HROW) experienced a significant pre-market plummet of 19.59% on Tuesday, as the stock opened sharply lower following the release of its latest financial results.

The sharp decline was driven by the company's fourth-quarter earnings report, which revealed earnings per share of $0.17, significantly missing the analyst consensus estimate of $0.38. Furthermore, the ophthalmic drugmaker issued its fiscal 2026 revenue guidance in the range of $350 million to $365 million, which fell below the average analyst estimate of approximately $386 million.

This combination of an earnings shortfall and weaker-than-anticipated forward outlook prompted a sell-off, with the stock extending losses from the previous trading session and underperforming the broader healthcare sector during the pre-market session.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10